Patient Group Direction for Vaxzevria COVID-19 vaccine

Document first published:
Page updated:
Topic:
,
Publication type:

This Patient Group Direction (PGD) is for the administration of Vaxzevria, COVID-19 vaccine (ChAdOx1-S [recombinant]), to individuals in accordance with the national COVID-19 vaccination programme in England.

 

Summary

Providers must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Updated 10 May 2022.

Summary

Providers must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Updated 10 May 2022.